Antibody engineering methods for CDR-site modification that preserve binding unlock lower-risk humanized therapeutics.
The method identifies specific antibody positions that can be mutated while keeping binding affinity largely intact, enabling CDR sequence changes during engineering and humanization. It’s technically significant because it targets “modify without significantly reducing binding” rather than trial-and-error, helping maintain antibody affinity during sequence redesign. Before expiry, companies typically needed licenses to use these exact antibody-position identification and CDR modification techniques for making improved binders.
Develop affinity-preserving humanized antibody therapeutics and diagnostic binders without relying on current antibody-engineering licenses.
The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody, in humanization methods, or in other antibody engineering methods.
Post a problem you're solving with this technology and connect with founders, investors, and researchers.